Subjects -> MEDICAL SCIENCES (Total: 8679 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (338 journals)
    - DENTISTRY (294 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (42 journals)
    - HEMATOLOGY (157 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (177 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2410 journals)
    - NURSES AND NURSING (369 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (386 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PSYCHIATRY AND NEUROLOGY (833 journals)
    - RESPIRATORY DISEASES (105 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (406 journals)

GASTROENTEROLOGY AND HEPATOLOGY (189 journals)                     

Showing 1 - 189 of 189 Journals sorted alphabetically
Abdominal Radiology     Hybrid Journal   (Followers: 22)
ACG Case Reports Journal     Open Access   (Followers: 1)
Acta Endoscopica     Hybrid Journal   (Followers: 1)
Acta Gastroenterologica Latinoamericana     Open Access   (Followers: 2)
Actualités Odonto-Stomatologiques     Open Access   (Followers: 4)
Adipositas - Ursachen, Folgeerkrankungen, Therapie     Hybrid Journal  
Advances in Diabetes and Metabolism     Open Access   (Followers: 30)
Advances in Digestive Medicine     Open Access   (Followers: 15)
Advances in Hepatology     Open Access   (Followers: 3)
AJP Gastrointestinal and Liver Physiology     Hybrid Journal   (Followers: 8)
Akademik Gastroenteroloji Dergisi / Turkish Journal of Academic Gastroenterology     Open Access  
Alimentary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 33)
Alimentary Pharmacology & Therapeutics Symposium Series     Hybrid Journal   (Followers: 2)
American Journal of Gastroenterology Supplements     Full-text available via subscription   (Followers: 7)
American Journal of Gastroenterology, The     Hybrid Journal   (Followers: 177)
Annals of Gastroenterological Surgery     Open Access   (Followers: 1)
Annals of Gastroenterology     Open Access   (Followers: 1)
Arab Journal of Gastroenterology     Full-text available via subscription   (Followers: 3)
Archives of Clinical Gastroenterology     Open Access   (Followers: 2)
Archives of Hepatitis Research     Open Access   (Followers: 2)
Arquivos de Gastroenterologia     Open Access   (Followers: 1)
Australian and New Zealand Continence Journal     Full-text available via subscription   (Followers: 4)
Avances en Odontoestomatologia     Open Access   (Followers: 1)
Best Practice & Research Clinical Gastroenterology     Full-text available via subscription   (Followers: 7)
BMC Gastroenterology     Open Access   (Followers: 15)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 32)
BMJ Open Gastroenterology     Open Access   (Followers: 10)
Canadian Journal of Gastroenterology & Hepatology     Open Access   (Followers: 4)
Case Reports in Gastroenterology     Open Access   (Followers: 4)
Case Reports in Gastrointestinal Medicine     Open Access   (Followers: 3)
Case Reports in Hepatology     Open Access   (Followers: 2)
Cellular and Molecular Gastroenterology and Hepatology     Open Access   (Followers: 4)
Clinical and Experimental Gastroenterology     Open Access  
Clinical and Molecular Hepatology     Open Access   (Followers: 2)
Clinical and Translational Gastroenterology     Open Access   (Followers: 1)
Clinical Diabetes     Full-text available via subscription   (Followers: 44)
Clinical Gastroenterology and Hepatology     Hybrid Journal   (Followers: 33)
Clinical Journal of Gastroenterology     Hybrid Journal   (Followers: 10)
Clinics and Research in Hepatology and Gastroenterology     Hybrid Journal   (Followers: 10)
Clinics and Research in Hepatology and Gastroenterology : X     Open Access   (Followers: 1)
Clinics in Liver Disease     Full-text available via subscription   (Followers: 12)
Colon & Rectum     Hybrid Journal   (Followers: 5)
coloproctology     Hybrid Journal   (Followers: 3)
Colorectal Disease     Hybrid Journal   (Followers: 12)
Comparative Hepatology     Open Access   (Followers: 3)
Current Bladder Dysfunction Reports     Hybrid Journal  
Current Colorectal Cancer Reports     Hybrid Journal   (Followers: 2)
Current Diabetes Reports     Hybrid Journal   (Followers: 30)
Current Gastroenterology Reports     Hybrid Journal   (Followers: 4)
Current Hepatitis Reports     Hybrid Journal   (Followers: 8)
Current Hepatology Reports     Hybrid Journal  
Current Opinion in Gastroenterology     Hybrid Journal   (Followers: 14)
Current Treatment Options in Gastroenterology     Hybrid Journal   (Followers: 6)
Der Gastroenterologe     Hybrid Journal   (Followers: 1)
Diabetes     Full-text available via subscription   (Followers: 576)
Diabetes Internacional     Open Access  
Diabetes Spectrum     Full-text available via subscription   (Followers: 17)
Diagnostic and Therapeutic Endoscopy     Open Access  
Dialysis & Transplantation     Hybrid Journal   (Followers: 6)
Digestion     Full-text available via subscription   (Followers: 4)
Digestive and Liver Disease     Hybrid Journal   (Followers: 15)
Digestive and Liver Disease Supplements     Full-text available via subscription   (Followers: 5)
Digestive Disease Interventions     Hybrid Journal  
Digestive Diseases     Full-text available via subscription   (Followers: 17)
Digestive Diseases and Sciences     Hybrid Journal   (Followers: 5)
Digestive Endoscopy     Hybrid Journal   (Followers: 3)
Diseases of the Colon & Rectum     Hybrid Journal   (Followers: 38)
Diseases of the Esophagus     Hybrid Journal  
Dysphagia     Hybrid Journal   (Followers: 206)
EMC - Técnicas Quirúrgicas - Aparato Digestivo     Full-text available via subscription  
Endoscopia     Open Access  
Endoscopy     Hybrid Journal   (Followers: 10)
Endoscopy International Open     Open Access  
Endoskopie heute     Hybrid Journal   (Followers: 1)
Esophagus     Hybrid Journal  
European Journal of Gastroenterology & Hepatology     Hybrid Journal   (Followers: 23)
Expert Review of Gastroenterology and Hepatology     Full-text available via subscription   (Followers: 9)
Frontline Gastroenterology     Hybrid Journal  
Gastric Cancer     Hybrid Journal   (Followers: 1)
Gastro-News     Full-text available via subscription   (Followers: 3)
Gastroenterologia Kliniczna. Postępy i Standardy     Open Access  
Gastroenterología y Hepatología     Full-text available via subscription  
Gastroenterología y Hepatología (English Edition)     Hybrid Journal  
Gastroenterología y Hepatología Continuada     Full-text available via subscription  
Gastroenterologie up2date     Hybrid Journal   (Followers: 3)
Gastroenterology     Hybrid Journal   (Followers: 244)
Gastroenterology (Gastroenterologìa)     Open Access   (Followers: 2)
Gastroenterology and Hepatology from bed to bench     Open Access   (Followers: 4)
Gastroenterology Clinics of North America     Full-text available via subscription   (Followers: 9)
Gastroenterology Insights     Open Access   (Followers: 2)
Gastroenterology Report     Open Access   (Followers: 2)
Gastroenterology Research     Open Access   (Followers: 6)
Gastroenterology Research and Practice     Open Access   (Followers: 1)
GastroHep     Hybrid Journal   (Followers: 1)
Gastrointestinal Cancer : Targets and Therapy     Open Access   (Followers: 3)
Gastrointestinal Disorders     Open Access  
Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 27)
Gastrointestinal Endoscopy Clinics of North America     Full-text available via subscription   (Followers: 9)
Gastrointestinal Tumors     Open Access  
GE Portuguese Journal of Gastroenterology     Open Access  
Gut     Hybrid Journal   (Followers: 233)
Gut Microbes     Full-text available via subscription   (Followers: 11)
Gut Pathogens     Full-text available via subscription   (Followers: 5)
Hemodialysis International     Hybrid Journal   (Followers: 3)
Hepatic Medicine: Evidence and Research     Open Access   (Followers: 5)
Hepatitis B Annual     Open Access   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 4)
Hepatitis Research and Treatment     Open Access   (Followers: 6)
Hepatobiliary & Pancreatic Diseases International     Full-text available via subscription   (Followers: 1)
Hepatology     Hybrid Journal   (Followers: 44)
Hepatology International     Hybrid Journal   (Followers: 7)
Hepatology Research     Hybrid Journal   (Followers: 15)
Hepatology, Medicine and Policy     Open Access  
Hernia     Hybrid Journal   (Followers: 6)
HPB: The official journal of the International Hepato Pancreato Biliary Association     Hybrid Journal   (Followers: 3)
Indian Journal of Gastroenterology     Open Access   (Followers: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 45)
Inflammatory Intestinal Diseases     Open Access   (Followers: 1)
Info Diabetologie     Full-text available via subscription   (Followers: 1)
International Journal of Celiac Disease     Open Access   (Followers: 3)
International Journal of Colorectal Disease     Hybrid Journal   (Followers: 10)
International Journal of Hepatology     Open Access   (Followers: 4)
International Journal of Stomatological Research     Open Access  
JGH Open     Open Access   (Followers: 1)
JMIR Diabetes     Open Access  
Journal Africain d'Hépato-Gastroentérologie     Hybrid Journal   (Followers: 1)
Journal für Gastroenterologische und Hepatologische Erkrankungen     Hybrid Journal  
Journal of Clinical Gastroenterology     Hybrid Journal   (Followers: 10)
Journal of Coloproctology     Open Access  
Journal of Crohn's and Colitis     Hybrid Journal   (Followers: 11)
Journal of Crohn's and Colitis Supplements     Full-text available via subscription   (Followers: 2)
Journal of Diabetes Research     Open Access   (Followers: 14)
Journal of Diabetology     Open Access   (Followers: 1)
Journal of Digestive Diseases     Hybrid Journal   (Followers: 2)
Journal of Digestive Endoscopy     Open Access   (Followers: 4)
Journal of Endometriosis and Pelvic Pain Disorders     Hybrid Journal  
Journal of Gastroenterology     Hybrid Journal   (Followers: 11)
Journal of Gastroenterology and Hepatology     Hybrid Journal   (Followers: 14)
Journal of Gastroenterology and Hepatology Research     Open Access   (Followers: 4)
Journal of Gastrointestinal Cancer     Hybrid Journal   (Followers: 3)
Journal of Gastrointestinal Oncology     Open Access   (Followers: 1)
Journal of Hepato-Biliary-Pancreatic Sciences     Hybrid Journal   (Followers: 4)
Journal of Hepatology     Hybrid Journal   (Followers: 24)
Journal of Obesity and Bariatrics     Open Access   (Followers: 1)
Journal of Obesity and Metabolic Research     Open Access   (Followers: 7)
Journal of Social Health and Diabetes     Open Access   (Followers: 2)
Journal of the Anus, Rectum and Colon     Open Access  
Journal of the Canadian Association of Gastroenterology     Open Access  
Journal of Viral Hepatitis     Hybrid Journal   (Followers: 7)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney International Supplements     Partially Free   (Followers: 4)
Liver Cancer     Open Access   (Followers: 1)
Liver International     Hybrid Journal   (Followers: 12)
Liver Transplantation     Hybrid Journal   (Followers: 9)
Methods in Enzymology     Full-text available via subscription   (Followers: 12)
Nature Reviews Gastroenterology & Hepatology     Full-text available via subscription   (Followers: 38)
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Neurogastroenterology & Motility     Hybrid Journal   (Followers: 2)
Nigerian Journal of Gastroenterology and Hepatology     Full-text available via subscription  
Obesity Science & Practice     Open Access   (Followers: 1)
Oncology, Gastroenterology and Hepatology Reports     Open Access   (Followers: 3)
Open Diabetes Journal     Open Access  
Open Journal of Gastroenterology     Open Access   (Followers: 2)
Pancreatology     Full-text available via subscription   (Followers: 3)
Revista Brasileira de Coloproctologia     Open Access  
Revista de Gastroenterología de México     Open Access  
Revista de Gastroenterología de México (English Edition)     Open Access  
Revista de Gastroenterología del Perú     Open Access  
Revista Española de Enfermedades Digestivas     Open Access  
Revista Estomatológica Herediana     Open Access  
Revista GEN     Open Access  
Revue de Stomatologie et de Chirurgie Maxillo-faciale     Full-text available via subscription   (Followers: 1)
Saudi Journal of Gastroenterology     Open Access   (Followers: 2)
Saudi Journal of Obesity     Open Access   (Followers: 1)
Scandinavian Journal of Gastroenterology     Hybrid Journal   (Followers: 10)
Seminars in Liver Disease     Hybrid Journal   (Followers: 8)
South African Gastroenterology Review     Full-text available via subscription  
Techniques in Coloproctology     Hybrid Journal   (Followers: 11)
Techniques in Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 2)
The Lancet Diabetes and Endocrinology     Full-text available via subscription   (Followers: 222)
Therapeutic Advances in Gastroenterology     Open Access   (Followers: 5)
Therapeutic Advances in Gastrointestinal Endoscopy     Open Access   (Followers: 2)
Türkiye Diyabet ve Obezite Dergisi     Open Access  
United European Gastroenterology Journal     Hybrid Journal   (Followers: 2)
Visceral Medicine     Full-text available via subscription  
Viszeralmedizin     Full-text available via subscription  
World Council of Enterostomal Therapists Journal     Full-text available via subscription  
World Journal of Gastroenterology     Open Access   (Followers: 4)
Zeitschrift für Gastroenterologie     Hybrid Journal   (Followers: 8)


Similar Journals
Journal Cover
Therapeutic Advances in Gastroenterology
Journal Prestige (SJR): 1.61
Citation Impact (citeScore): 4
Number of Followers: 5  

  This is an Open Access Journal Open Access journal
ISSN (Print) 1756-283X - ISSN (Online) 1756-2848
Published by Sage Publications Homepage  [1090 journals]
  • Burden of drug use for gastrointestinal symptoms and functional
           gastrointestinal disorders in France: a national study using reimbursement
           data for 57 million inhabitants

    • Authors: Philippe Tuppin, Sébastien Rivière, David Deutsch, Christelle Gastaldi-Menager, Jean-Marc Sabaté
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Gastrointestinal therapeutic drugs (GTDs) are extensively prescribed. The aim of this study was to investigate the characteristics of GTD use in a large population: the French general health scheme beneficiaries (87% of the 66 million inhabitants) in 2016.Methods:The national health data system was used to identify individual characteristics, diseases and GTD classes reimbursed, together with the costs, using anatomical therapeutic chemical class.Results:Among the 57.5 million individuals included, 45% received at least one reimbursement among the 130 million prescriptions reimbursed (90% prescribed by a general practitioner): proton-pump inhibitors (PPI; A02BC: 24%), drugs for functional gastrointestinal disorders (A03: 20%), drugs for constipation (A06: 10%), antidiarrheals, intestinal anti-inflammatory/anti-infective agents (A07: 10%), antiemetics and antinauseants (A04: 7%), other drugs for acid-related disorders (A02X: 6%), other drugs for peptic ulcer and gastro-oesophageal reflux disease (A02BX: 4.5%), antacids (A02A: 1.5%). The overall cost of reimbursed GTDs was €707 million and the mean cost per user was €28. Marked variations were observed according to age, sex, and disease. The rates of at least one reimbursement among infants were A07: 28%, A03: 17%, A02BX: 9%, A02X: 7%, A02BC: 6% and A06: 5%. Women more frequently received a reimbursement than men for each GTD class. Reimbursement rates also varied according to health status (end-stage renal disease A02BC: 66%, pregnancy A03: 53%, A04: 11%), treatments (people with at least six reimbursements for nonsteroidal anti-inflammatory drugs in 2016 A02BC: 62%). Chronic GTD use (>10 reimbursements/year) was observed in 19% of people with at least one A02BC reimbursement, A02BX: 11%, A03: 7%, A04: 2%, A06: 17% and A07: 3%.Conclusions:This study demonstrates extensive and chronic use of GTD in France, raising the question of their relevance according to current guidelines. They must be disseminated to general practitioners, who are the main prescribers of these drugs.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-07-12T07:27:42Z
      DOI: 10.1177/1756284819853790
      Issue No: Vol. 12 (2019)
  • Current status of first- and second-line Helicobacter pylori eradication
           therapy in the metropolitan area: a multicenter study with a large number
           of patients

    • Authors: Hideki Mori, Hidekazu Suzuki, Fumio Omata, Tatsuhiro Masaoka, Daisuke Asaoka, Kohei Kawakami, Shigeaki Mizuno, Naoto Kurihara, Akihito Nagahara, Nobuhiro Sakaki, Masayoshi Ito, Yo Kawamura, Masayuki Suzuki, Yuji Shimada, Hitoshi Sasaki, Takeshi Matsuhisa, Akira Torii, Toshihiro Nishizawa, Tetsuya Mine, Toshifumi Ohkusa, Takashi Kawai, Kengo Tokunaga, Shin’ichi Takahashi
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In this study, we examined the trend of the eradication rate of H. pylori in the metropolitan area and examined factors concerning successful eradication.Methods:We collected data from 20 hospitals in the Tokyo metropolitan area on patients who received first-line eradication therapy with a proton-pump inhibitor (PPI)/P-CAB, amoxicillin, and clarithromycin for 1 week and second-line eradication therapy with a PPI/P-CAB, amoxicillin, and metronidazole for 1 week from 2013 to 2018. The annual eradication rate and associated factors for successful eradication were analyzed.Results:We collected data of 4097 and 3572 patients in the first- and second-line eradication therapies, respectively. The eradication rate decreased from 2013 to 2014 and increased again from 2015 to 2018 with the first-line therapy [the eradication rates in 2013, 2014, 2015, 2016, 2017 and 2018 were 71.8%, 63.7%, 78.5%, 84.6%, 89.7 and 90.1%, respectively, in the per protocol (PP)]. The second-line eradication rates were 90.0%, 82.6%, 88.8%, 87.5%, 91.8% and 90.1% in 2013, 2014, 2015, 2016, 2017 and 2018, respectively, in PP. Vonoprazan was an independent factor for successful eradication in not only first-line, but also second-line eradication. Age over 75 years was an independent factor for eradication failure in both first- and second-line eradication therapies.Conclusion:The eradication rate improved from 2015 to 2018 with the first-line therapy because of the introduction of vonoprazan in the market. The eradication rates with first- and second-line regimens in elderly patients were lower than those in younger patients.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-07-04T12:06:33Z
      DOI: 10.1177/1756284819858511
      Issue No: Vol. 12 (2019)
  • The efficacy of prophylactic pancreatic stents against complications of
           post-endoscopic papillectomy or endoscopic ampullectomy: a systematic
           review and meta-analysis

    • Authors: Yining Wang, Miao Qi, Yuanzhen Hao, Junbo Hong
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Endoscopic resection has been increasingly adopted for neoplasms in the major duodenal papilla. Previous studies have reached varying conclusions on whether prophylactic pancreatic stent (PS) placement is an effective measure against post-procedure complications. We aimed to investigate whether PS could reduce the incidence of post-procedure complications.Methods:The PubMed, Cochrane Library, and EMBASE databases were systematically searched from the inception dates to 25 December 2018 to identify all randomized controlled trials (RCTs) and retrospective cohort studies (RCSs) comparing prophylactic PS and no PS against post-procedure complications. The main outcomes measurements were post-procedure pancreatitis, bleeding, perforation and late papillary stenosis.Results:23 RCSs (1001 subjects) and 2 RCTs met the inclusion criteria. Meta-analysis of the RCSs showed that prophylactic PS decreased the odds of post-procedure pancreatitis (OR, 0.71; 95% CI, 0.36–1.40; p = 0.325) as well as late papillary stenosis (OR, 0.35; 95% CI, 0.07–1.75; p = 0.200; I2 =0%) and increased the odds of bleeding (OR, 1.32; 95% CI, 0.50–3.46; p = 0.572; I2 = 0%) and perforation (OR, 2.25; 95% CI, 0.33–15.50; p = 0.412; I2 = 0%) but not significantly. Sensitivity analysis illustrated prophylactic PS significantly decreased the risk of post-procedure pancreatitis (OR, 0.44; 95% CI, 0.24–0.80; p = 0.007).Conclusions:PS placement was prophylactic against post-procedure complications although not significantly. Sensitivity analysis suggests the significant effect of prophylactic PS against post-procedure pancreatitis. More RCTs are required to validate the statistical significance of our results and potentially relevant characteristics improving the prophylactic efficacy of stents.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-26T10:38:55Z
      DOI: 10.1177/1756284819855342
      Issue No: Vol. 12 (2019)
  • The anti-inflammatory potential of diet and nonalcoholic fatty liver
           disease: the ATTICA study

    • Authors: Stefanos Tyrovolas, Demosthenes B. Panagiotakos, Ekavi N. Georgousopoulou, Christina Chrysohoou, John Skoumas, William Pan, Dimitrios Tousoulis, Christos Pitsavos
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Nonalcoholic fatty liver disease (NAFLD) is correlated with low-grade inflammation and dietary habits. Until today, there have been limited epidemiologic data assessing the role of diet’s inflammatory potential on NAFLD. The aim was to evaluate the relationship between an anti-inflammatory diet, as reflected by the Dietary Anti-Inflammation Index (D-AII), and NAFLD among cardiovascular disease (CVD)-free adults.Methods:ATTICA is a prospective, population-based study that recruited 3042 adults without pre-existing CVD from the Greek population (Whites; age ⩾18 years; 1514 men and 1528 women). D-AII was calculated using a standard procedure. The baseline study captured various sociodemographic, lifestyle and clinical characteristics as well as hepatic markers. These were used to calculate four NAFLD assessment indices: triglyceride-glucose (TyG) index, fatty liver index (FLI), hepatic steatosis index (HSI), and NAFLD Fatty Liver Score (NAFLD-FLS). Specific cutoffs were applied to capture NAFLD.Results:D-AII showed a significant inverse association with NAFLD, applying the four indices with NAFLD cutoffs [odds ratio (OR) with 95% confidence interval (CI); TyG (0.95, 0.93–0.98); HSI (0.89, 0.86–0.92); FLI (0.88, 0.85–0.91); NAFLD-FLS (0.89, 0.86–0.92)], after adjusting for various confounders. Participants in the highest D-AII tertile had lower odds of having NAFLD, compared with those in the lowest D-AII tertile [(OR, 95% CI); TyG (0.33, 0.24–0.47); HSI (0.13, 0.08–0.23); FLI (0.05, 0.02–0.11); NAFLD-FLS (0.13, 0.07–0.23)]. Anti-inflammatory nutrition was related to lower odds of NAFLD among daily alcohol drinkers and individuals with metabolic syndrome.Conclusions:Anti-inflammatory diet is an important predictor of NAFLD among adults without pre-existing CVD. Adherence to a high anti-inflammatory diet seems to contribute to NAFLD prevention.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-24T06:58:48Z
      DOI: 10.1177/1756284819858039
      Issue No: Vol. 12 (2019)
  • Insights into the evolving role of the gut microbiome in nonalcoholic

    • Authors: Marialena Mouzaki, Rohit Loomba
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Nonalcoholic fatty liver disease (NAFLD) is diagnosed across the age spectrum and contributes to significant morbidity and mortality. The pathophysiology of NAFLD is not entirely understood; however, recent evidence has implicated the intestinal microbiome. Through the effects on host appetite, energy expenditure, digestion, gene expression, intestinal permeability, as well as immune activation, a dysbiotic microbiome can contribute to the development and progression of the hepatocellular steatosis, inflammation and fibrosis seen in the context of NAFLD. As such, intestinal microbiota and products of their metabolism have been targeted as treatment approaches for NAFLD.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-24T05:21:57Z
      DOI: 10.1177/1756284819858470
      Issue No: Vol. 12 (2019)
  • The efficacy and safety of rifaximin-α: a 2-year observational study of
           overt hepatic encephalopathy

    • Authors: Rosalie C. Oey, Lennart E.M. Buck, Nicole S. Erler, Henk R. van Buuren, Robert A. de Man
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:After 5  years since the registration of rifaximin-α as a secondary prophylaxis for overt hepatic encephalopathy (HE) in the Netherlands, we aimed to evaluate the use of hospital resources and safety of rifaximin-α treatment in a real-world setting.Methods:We carried out prospective identification of all patients using rifaximin-α for overt HE. We assessed hospital resource use, bacterial infections, and adverse events during 6-month episodes before and after rifaximin-α initiation.Results:During 26 months we included 127 patients [71.7% male; median age 60.8 years (interquartile range: 56.2–66.1); median model for end-stage liver disease (MELD) score 15.0 (interquartile range: 12.1–20.4); 98% using lactulose treatment]. When comparing the first 6 months after rifaximin-α initiation with the prior 6 months, HE-related hospital admissions decreased (0.86 to 0.41 admissions/patient; p 
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-24T05:20:43Z
      DOI: 10.1177/1756284819858256
      Issue No: Vol. 12 (2019)
  • Long-term follow up after switching from original infliximab to an
           infliximab biosimilar: real-world data

    • Authors: María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas, Federico Argüelles-Arias
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce. Here, we assessed the long-term efficacy data, loss of response and safety after switching from infliximab to CT-P13 in patients with inflammatory bowel disease.Methods:This was a prospective single-center observational study involving patients with moderate-to-severe Crohn’s disease and ulcerative colitis switched from infliximab to CT-P13 treatment and reviewed up to 24 months. Efficacy and loss of response were measured using the Harvey–Bradshaw (HB) index and partial Mayo score for patients with Crohn’s disease and ulcerative colitis respectively. C-reactive protein, infliximab drug levels, adverse events and antidrug antibodies were also monitored throughout the study.Results:A total of 64 patients with Crohn’s disease and 36 patients with ulcerative colitis were included. Most of them (72%) remained on CT-P13. Overall, 28% of patients discontinued the therapy due to loss of response, adverse events or long-lasting clinical remission. Remission at 18 and 24 months occurred in 69.9% and 68.5% of patients, respectively. Dose increase was performed in 22% of patients, with remission being reached in 60% of them. HB index, partial Mayo score, C-reactive protein and infliximab drug levels did not show significant changes. Serious adverse events were reported in 14% of patients. Overall, two patients developed low levels of antidrug antibodies.Conclusions:Most of the patients switching from original infliximab were maintained on CT-P13 at 2 years of follow up with a good profile of efficacy and safety.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-19T05:30:21Z
      DOI: 10.1177/1756284819858052
      Issue No: Vol. 12 (2019)
  • The irreversible HCV-associated risk of gastric cancer following
           interferon-based therapy: a joint study of hospital-based cases and
           nationwide population-based cohorts

    • Authors: Chun-Wei Chen, Jur-Shan Cheng, Tai-Di Chen, Puo-Hsien Le, Hsin-Ping Ku, Ming-Ling Chang
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Hepatitis C virus (HCV) infection causes many extrahepatic malignancies; whether it increases gastric cancer risk and the risk reverses after anti-HCV therapy remain elusive.Method:A nationwide population-based cohort study of Taiwan National Health Insurance Research Database (TNHIRD) was conducted. In parallel, the risk factors and HCV-core-protein expressions were surveyed in gastric cancer patients from a tertiary care center.Results:From 2003 to 2012, of 11,712,928 patients, three 1:4:4, propensity-score-matched TNHIRD cohorts including HCV-treated (7545 patients with interferon-based therapy ⩾ 6 months), HCV-untreated (n = 30,180), and HCV-uninfected cohorts (n = 30,180) were enrolled. The cumulative incidences of gastric cancer [HCV-treated: 0.452%; 95% confidence interval (CI): 0.149–1.136%; HCV-untreated: 0.472%; 95% CI: 0.274–0.776%; HCV-uninfected: 0.146%; 95% CI 0.071–0.280%] were lowest in HCV-uninfected cohort (p = 0.0028), but indifferent between treated and untreated cohorts. HCV infection [hazards ratio (HR): 2.364; 95% CI: 1.337–4.181], male sex (HR: 1.823; 95% CI: 1.09–3.05) and age ⩾ 49 years (HR: 3.066; 95% CI: 1.56–6.026) were associated with incident gastric cancers. Among 887 (males: 68.4%; mean age: 66.5 ± 12.9 years, 2008–2018) hospitalized gastric cancer patients, HCV Ab-positive rate was 7.8%. None of the investigated factors exhibited different rates between HCV Ab-positive and Ab-negative patients. No HCV-core-positive cells were demonstrated in gastric cancer tissues.Conclusions:HCV infection, male sex and old age were risk factors for gastric cancer development. HCV-associated gastric cancer risk might be neither reversed by interferon-based therapy, nor associated with in situ HCV-core-related carcinogenesis.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-18T05:47:22Z
      DOI: 10.1177/1756284819855732
      Issue No: Vol. 12 (2019)
  • Clinical and endoscopic features of severe acute gastrointestinal bleeding
           in elderly patients treated with direct oral anticoagulants: a multicentre

    • Authors: David Deutsch, Pauline Romegoux, Christian Boustière, Jean-Marc Sabaté, Robert Benamouzig, Pierre Albaladejo
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:The aim of the study was to describe the clinical and endoscopic characteristics and management of severe acute gastrointestinal (GI) bleeding in patients treated with direct oral anticoagulants (DOACs).Methods:Patients hospitalized for severe GI bleeding under DOAC therapy were identified in 36 centres between June 2013 and March 2016. Clinical outcomes including re-bleeding, major cerebral and cardiovascular events or all-cause mortality were assessed initially and 30 days after admission.Results:A total of 59 patients with anonymized detailed endoscopy reports for severe GI bleeding were considered. Mean age was 79.3 ± 10.0 years and 61.3% of patients were men. Patients had histories of hypertension (65.6%), heart failure (29.5%), coronary artery disease (27.9%), stroke (19.7%) and peripheral vascular disease (36.1%). Life-threatening bleeding was observed in 42.6%. Mean number of packed red blood cells transfused was 3.4 (range 1–31). Aetiology of bleeding (identified in 66.2% of cases) was peptic gastroduodenal ulcers (22%), diverticula (11.9%), angiodysplasia (8.5%), colorectal neoplasia (5.1%) and anorectal causes (5.1%). Endoscopic haemostasis was performed in 37.7% of patients. A low haemoglobin level was predictive of life-threatening bleeding and death in multivariate analysis. All-cause mortality rate at day 30 was 11.8%.Conclusions:In this cohort of elderly patients with multiple comorbidities treated with DOACs, the main cause of severe acute GI bleeding was peptic gastroduodenal ulcer and mortality was high.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-17T09:36:39Z
      DOI: 10.1177/1756284819851677
      Issue No: Vol. 12 (2019)
  • Pathophysiology and management of diabetic gastroenteropathy

    • Authors: Theresa Meldgaard, Jutta Keller, Anne Estrup Olesen, Søren Schou Olesen, Klaus Krogh, Mette Borre, Adam Farmer, Birgitte Brock, Christina Brock, Asbjørn Mohr Drewes
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Polyneuropathy is a common complication to diabetes. Neuropathies within the enteric nervous system are associated with gastroenteropathy and marked symptoms that severely reduce quality of life. Symptoms are pleomorphic but include nausea, vomiting, dysphagia, dyspepsia, pain, bloating, diarrhoea, constipation and faecal incontinence. The aims of this review are fourfold. First, to provide a summary of the pathophysiology underlying diabetic gastroenteropathy. Secondly to give an overview of the diagnostic methods. Thirdly, to provide clinicians with a focussed overview of current and future methods for pharmacological and nonpharmacological treatment modalities. Pharmacological management is categorised according to symptoms arising from the upper or lower gut as well as sensory dysfunctions. Dietary management is central to improvement of symptoms and is discussed in detail, and neuromodulatory treatment modalities and other emerging management strategies for diabetic gastroenteropathy are discussed. Finally, we propose a diagnostic/investigation algorithm that can be used to support multidisciplinary management.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-17T07:10:38Z
      DOI: 10.1177/1756284819852047
      Issue No: Vol. 12 (2019)
  • Hypertension control and risk of colonic diverticulosis

    • Authors: Li-Xian Yeo, Tzu-Hsiang Tseng, Wei-Liang Chen, Tung-Wei Kao, Li-Wei Wu, Wen-Hui Fang, Yaw-Wen Chang, Tao-Chun Peng
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:The prevalence of diverticulosis has increased in our aging population, but the risk factors for diverticulosis are not fully understood. The role of hypertension in the risk of diverticulosis remains uncertain. This study investigated whether hypertension is associated with asymptomatic colorectal diverticulosis.Methods:This study enrolled asymptomatic patients who received a colonoscopy as part of a health check. Hypertension was defined by actual measured blood pressure. Logistic regression models were used to examine the relationship between hypertension and diverticulosis. In addition, we established three logistic regression models for covariate adjustment, and further stratified patients with hypertension into three subgroups based on their type of hypertension.Results:The study group consisted of 2748 participants, including 141 participants with diverticulosis and 2607 participants without diverticulosis. After adjustments for potential covariates, the odds ratio (OR) for having diverticulosis was 1.83 (95% confidence interval, 1.21–2.75, p = 0.004) in the hypertension group compared with the group without hypertension. In subgroup analyses, hypertension without antihypertensive medication use, and hypertension despite the use of antihypertensive medication were also significantly associated with the occurrence of asymptomatic diverticulosis (OR = 1.73, p = 0.028; OR = 2.07, p = 0.013, respectively). Current normal blood pressure under antihypertensive drug therapy was not associated with diverticulosis (OR = 1.74, p = 0.092).Conclusions:Our findings suggest a positive association between hypertension and diverticulosis. Participants with poorly controlled blood pressure were found to have a higher risk of asymptomatic diverticulosis. Our study presents epidemiologic evidence for future prevention strategies against diverticulosis.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-17T07:08:52Z
      DOI: 10.1177/1756284819855734
      Issue No: Vol. 12 (2019)
  • Targeting mucosal healing in Crohn’s disease: what the clinician
           needs to know

    • Authors: Entcho Klenske, Christian Bojarski, Maximilian Waldner, Timo Rath, Markus F. Neurath, Raja Atreya
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      In recent years, mucosal healing has emerged as a key therapeutic goal in the clinical management of patients with Crohn’s disease, as it has been associated with improved long-term clinical outcomes. With the vast improvements in endoscopic imaging techniques and the increase in available treatment options, which reportedly are able to induce mucosal healing, the practising physician is left to wonder: how is endoscopic mucosal healing exactly defined in Crohn’s disease, and how can it effectively be achieved and monitored in daily clinical practice' Within this review, we will give an overview of the ongoing debate about the definition of mucosal healing and the modalities to monitor inflammation, and finally present available therapies with the capacity to induce mucosal healing.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-14T07:11:05Z
      DOI: 10.1177/1756284819856865
      Issue No: Vol. 12 (2019)
  • The ‘totality-of-the-evidence’ approach in the development of
           PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in
           all indications of the reference product

    • Authors: Joseph E. McClellan, Hugh D. Conlon, Michael W. Bolt, Vatche Kalfayan, Rameshraja Palaparthy, Muhammad I. Rehman, Carol F. Kirchhoff
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      The ‘totality-of-the-evidence’ biosimilarity concept requires that sufficient structural, functional, nonclinical, and clinical data are acquired in a stepwise manner, to demonstrate that no clinically meaningful differences in quality, safety, or efficacy are observed compared with the reference product. We describe the totality of the evidence for PF-06438179/GP1111 (PF-SZ-IFX; IXIFI™ [infliximab-qbtx]/Zessly®) that supported its approval as an infliximab (IFX) biosimilar for all eligible indications of reference IFX (ref-IFX; Remicade®) in Europe and in the US. Analytical similarity involving in vitro assays capable of distinguishing structural or functional differences between PF-SZ-IFX and ref-IFX formed a foundation for the biosimilarity exercise. Differences identified in N-glycosylation and charge heterogeneity were found not to impact the results in in vitro biological assays reflective of the pharmacology underlying the mechanisms of action (tumor necrosis factor binding, reverse signaling, antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity) of IFX across disease indications. Similarity was assessed in a comparative clinical pharmacokinetic study and in a clinical efficacy and safety study in patients with rheumatoid arthritis, where therapeutic equivalence between PF-SZ-IFX and ref-IFX provided confirmatory evidence of biosimilarity, and, when coupled with the analytical similarity already established, supported extrapolation to all eligible disease indications of ref-IFX.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-13T09:12:57Z
      DOI: 10.1177/1756284819852535
      Issue No: Vol. 12 (2019)
  • An expansion study of genotype-driven weekly irinotecan and capecitabine
           in combination with neoadjuvant radiotherapy for locally advanced rectal
           cancer with UGT1A1 *1*1 genotype

    • Authors: Yun Guan, Yunzhu Shen, Ye Xu, Chao Li, Jingwen Wang, Weilie Gu, Peng Lian, Dan Huang, Sanjun Cai, Zhen Zhang, Ji Zhu
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:In our previous dose-escalation study, we uncovered the maximum tolerated dose (MTD) of weekly irinotecan was escalated to 80 mg/m2 and 65 mg/m2 for UDP glucuronosyltransferase family 1 member A1 (UGT1A1) *1*1 and *1*28 rectal cancer patients in neoadjuvant chemoradiotherapy (nCRT). This is an expansion study for *1*1 patients.Methods:Patients with clinical stage T3–4, N0–2 rectal cancer eligible for preoperative chemoradiotherapy were screened for the UGT1A1*28 genotype. A total of 52 patients with the *1*1 genotype were enrolled. Whole-pelvic intensity-modulated radiation therapy was given in 50 Gy/25 fractions. Concurrently, irinotecan of 80 mg/m2 and capecitabine of 625 mg/m2 twice daily from Monday to Friday were administered weekly. Primary endpoint was toxicities; secondary endpoints included pathological complete response (pCR), tumour-regression grading, treatment compliance, overall survival, local recurrence and disease-free survival.Results:All patients completed capecitabine-based radiotherapy as scheduled, and 42 (81%) patients completed more than three cycles of weekly irinotecan. Overall, grade 3/4 toxicities were observed in 20 cases, including 11 leucopenia, 10 neutropenia and 12 diarrhoea. Forty-three patients (83%) underwent a radical surgery, and 12 were evaluated as pCR. Another four patients accepted a watch-and-wait strategy because of clinical complete response (CCR).Conclusions:Our data demonstrated manageable toxicities and an encouraging CCR rate for UGT1A1 *1*1 genotype in an enhanced neoadjuvant therapy. A phase III trial is ongoing to evaluate the value of irinotecan in neoadjuvant therapy (CinClare) [ identifier: NCT02605265].
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-07T05:26:07Z
      DOI: 10.1177/1756284819852293
      Issue No: Vol. 12 (2019)
  • Risk factors for Barrett’s esophagus in young adults who underwent upper
           gastrointestinal endoscopy in a health examination center

    • Authors: Pin-Chieh Wu, Yan-Hua Chen, Fu-Zong Wu, Kung-Hung Lin, Chiao-Lin Hsu, Chi-Shen Chen, Yu-Hsun Chen, Po-Hsiang Lin, Guang-Yuan Mar, Hsien-Chung Yu
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Barrett’s esophagus (BE) is a premalignant condition with increased incidence worldwide both in old and young individuals. However, the role of certain potential risk factors remains unclear in young adults (< 50 years). We aimed to determine the risk factors of BE in young adults.Methods:A total of 4943 young adults who underwent upper gastrointestinal endoscopy at our health check-up center were enrolled. The diagnosis of BE was based on histological confirmation. We analyzed demographic factors, laboratory data, potential risk factors such as smoking, alcohol consumption, presence of gastroesophageal reflux disease (GERD) symptoms, and metabolic syndrome for the risk of BE by using binary logistic regression analysis.Results:The prevalence of BE was 1.8% (88/4943). Male sex, the presence of GERD symptoms, and smoking were three significant risk factors related to BE. Furthermore, participants who had smoked for 10 pack-years or more had increased risk of BE with dose-dependent phenomenon (p trend < 0.001). The proportion of BE in male participants with both GERD symptoms and a smoking history of 10 pack-years or more was as high as 10.3% (16/155).Conclusions:Significant risk factors of BE in young adults are male sex, the presence of GERD symptoms, and smoking. The risk also increases with an increase in cumulative exposure to smoking.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-06-03T11:31:26Z
      DOI: 10.1177/1756284819853115
      Issue No: Vol. 12 (2019)
  • Insights into the treatment of inflammatory bowel disease in pregnancy

    • Authors: Sarah E. Shannahan, Jonathan M. Erlich, Mark A. Peppercorn
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Patients diagnosed with inflammatory bowel disease (IBD) are most commonly diagnosed in late adolescence or early adulthood, with half of patients being diagnosed before age 32, thus impacting peak years of reproduction and family planning. While controlled IBD has no negative effects on the ability to conceive, there is overall a trend towards voluntary childlessness due to patients’ concerns for adverse fetal outcomes from underlying IBD and from adverse medication effects. Active disease at the time of conception is associated with worsening disease activity during pregnancy and carries a higher risk of poor fetal outcomes. It is therefore important to maintain remission during pregnancy, which is often achieved with pharmacologic therapy. The goal of this paper is to provide a comprehensive review of the current literature and safety data for pharmacologic treatment of IBD in pregnancy, in breastfeeding women, and in men planning to have children.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-28T05:52:03Z
      DOI: 10.1177/1756284819852231
      Issue No: Vol. 12 (2019)
  • New biologics and small molecules in inflammatory bowel disease: an update

    • Authors: João Sabino, Bram Verstockt, Séverine Vermeire, Marc Ferrante
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Inflammatory bowel disease (IBD) is a spectrum of immune-mediated inflammatory disorders with a complex multifactorial pathogenesis, where different pathways may predominate in different individuals. This complexity will most likely require a panoply of drugs targeting different pathways if one wants to treat to steroid-free sustained remission and mucosal healing. Presently, the mainstay of medical management of IBD is based on 5-aminosalicylates, corticosteroids, thiopurines, methotrexate, antitumor necrosis factor, anti-alpha4 beta7 (α4β7) integrin and anti-interleukin (IL)-12/IL-23 therapies. The discovery of new pathways involved in the pathogenesis of IBD resulted in new drugs targeting Janus kinase/signal transducers and activators of transcription, IL-6, spingosine-1-phosphate, and phosphodiesterase 4, among others. These new therapies might result in more advantageous safety profiles. Several of these new drugs have already been successfully tested in other inflammatory disorders, such as psoriasis or rheumatoid arthritis. In this review, evidence from phase II and phase III randomized controlled clinical trials in patients with IBD involving new biologicals and small molecules are summarized.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-27T05:24:04Z
      DOI: 10.1177/1756284819853208
      Issue No: Vol. 12 (2019)
  • EpidemIBD: rationale and design of a large-scale epidemiological study of
           inflammatory bowel disease in Spain

    • Authors: María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar Robledo, Cristina Rodríguez, Beatriz Sicilia, Emilio Torrella, Ana Garre, Esther García-Esquinas, Fernando Rodríguez-Artalejo, Javier P. Gisbert
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes.Methods:This multicenter, population-based incidence cohort study included patients aged>18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded.Results:The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up.Conclusions:The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-21T08:19:03Z
      DOI: 10.1177/1756284819847034
      Issue No: Vol. 12 (2019)
  • Efficacy and safety of a ready-to-drink bowel preparation for colonoscopy:
           a randomized, controlled, non-inferiority trial

    • Authors: Lawrence Hookey, Gerald Bertiger, Kenneth Lee Johnson, Julia Ayala, Yodit Seifu, Stuart P Brogadir
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:We performed a randomized, controlled, assessor-blinded, multicenter, non-inferiority (NI) study to compare the safety and efficacy of a ready-to-drink formulation of sodium picosulfate, magnesium oxide, and citric acid (SPMC oral solution) with a powder formulation (P/MC powder) for oral solution.Methods:Eligible participants (adults undergoing elective colonoscopy) were randomized 1:1 to split-dose SPMC oral solution or P/MC powder. The primary efficacy endpoint assessed overall colon-cleansing quality with the Aronchick Scale (AS), and the key secondary efficacy endpoint rated quality of right colon cleansing with the Boston Bowel Preparation Scale (BBPS). Assessments were performed by a treatment-blinded endoscopist. Tolerability was assessed using the Mayo Clinic Bowel Prep Tolerability Questionnaire. Safety assessments included adverse events and laboratory evaluations.Results:The study included 901 participants: 448 for SPMC oral solution; 453 for P/MC powder. SPMC oral solution demonstrated non-inferiority to P/MC powder {87.7% (393/448) responders versus 81.5% (369/453) responders [difference (95% confidence interval): 6.3% (1.8, 10.9)]}. The key secondary efficacy objective assessing the right colon was also met. According to the prespecified hierarchical testing, after meeting the primary and key secondary objectives, SPMC oral solution was tested for superiority to P/MC powder for the primary endpoint (p = 0.0067). SPMC oral solution was well tolerated. Most common adverse events were nausea (3.1% versus 2.9%), headache (2.7% versus 3.1%), hypermagnesemia (2.0% versus 5.1%), and vomiting (1.3% versus 0.7%) for SPMC oral solution and P/MC powder, respectively.Conclusions:Ready-to-drink SPMC oral solution showed superior efficacy of overall colon cleansing compared with P/MC powder, with similar safety and tolerability.[ identifier: NCT03017235.]
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-20T05:57:23Z
      DOI: 10.1177/1756284819851510
      Issue No: Vol. 12 (2019)
  • Tofacitinib in the treatment of ulcerative colitis: efficacy and safety
           from clinical trials to real-world experience

    • Authors: Ferdinando D’Amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Tofacitinib is an oral small molecule directed against the JAK/STAT pathway, blocking the inflammatory cascade. Oral formulation of tofacitinib has recently been approved for the treatment of patients with moderate–severe ulcerative colitis. Its efficacy and safety have been demonstrated in three phase III clinical trials and confirmed by promising real-life data. The purpose of this review is to summarize the available evidence on the efficacy and safety of tofacitinib and to define its role and position in the treatment algorithms for patients with ulcerative colitis.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-16T08:29:25Z
      DOI: 10.1177/1756284819848631
      Issue No: Vol. 12 (2019)
  • Management of Clostridioides difficile colitis: insights for the

    • Authors: Srishti Saha, Sahil Khanna
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Clostridioides difficile infection (CDI) is a common cause of diarrhea in both inpatient and outpatient settings. The last few years have seen major changes in the treatment spectrum of CDI, most notably, recommendations against using metronidazole for initial CDI, the addition of fidaxomicin and bezlotoxumab, and emergence of microbial replacement therapies. Several other therapies are undergoing clinical trials. This narrative review focuses on the treatment of CDI with a summary of literature on the newer modalities and the treatment guidelines issued by Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-05-07T06:42:07Z
      DOI: 10.1177/1756284819847651
      Issue No: Vol. 12 (2019)
  • Acute and subacute effects of oropharyngeal sensory stimulation with TRPV1
           agonists in older patients with oropharyngeal dysphagia: a biomechanical
           and neurophysiological randomized pilot study

    • Authors: Noemí Tomsen, Omar Ortega, Laia Rofes, Viridiana Arreola, Alberto Martin, Lluís Mundet, Pere Clavé
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Older people with oropharyngeal dysphagia (OD) present a decline in pharyngeal sensory function. The aim of this proof-of-concept study was to assess the biomechanical and neurophysiological effects of acute and subacute oropharyngeal sensory stimulation with transient receptor potential vanilloid 1 (TRPV1) agonists (capsaicinoids) in older patients with OD.Methods:We studied the effect of a single dose versus multiple doses (2 weeks) of oral capsaicin treatment (10–5 M) or placebo in 28 older patients with OD (81.2 ± 4.6 years) using videofluoroscopy (penetration-aspiration scale [PAS], timing of swallow response) and electroencephalography (EEG) (latency and amplitude of pharyngeal event-related potential [ERP]).Results:Acute stimulation by capsaicinoids 10–5 M did not improve swallow function and did not produce significant changes in pharyngeal ERP. In contrast, after 10 days of treatment, patients presented a clinically relevant and statistically significant reduction in the laryngeal vestibule closure (LVC) time (22.5%, p = 0.042), and in the PAS (24.2%, p = 0.038), compared with the placebo group. EEG results showed a reduction in the latency of the N1 peak (28.6%, p = 0.007) and an increase of the amplitude of the P1-N2 (59.4%, p = 0.038) and the N2-P2 (43.6%, p = 0.050) peaks. We observed a strong and significant correlation between the reduction in the latency of the N1 peak and change in LVC time after subacute treatment (r = 0.750, p = 0.003).Conclusions:After 2 weeks of treatment, oropharyngeal sensory stimulation with capsaicinoids induced cortical changes that were correlated with improvements in swallowing biomechanics in older patients with OD. These results further show that sensory stimulation by TRPV1 agonists can become a useful pharmacological treatment for older patients with OD.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-30T10:25:48Z
      DOI: 10.1177/1756284819842043
      Issue No: Vol. 12 (2019)
  • Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and
           duodenal receptor expression in children with and without celiac disease

    • Authors: Marianna Rachmiel, Gilad Ben-Yehudah, Haim Shirin, Efrat Broide
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Variability in glucagon-like peptide (GLP)-1 and GLP-2 plasma concentrations has been suggested in Celiac disease (CD), with inconclusive results. We assessed the association between serum levels of GLP-1 and GLP-2 and their duodenal receptor expression in children with and without CD.Methods:This was a two-part, cross-sectional and prospective cohort study. Group assignment, performed after duodenal samples for mRNA expression of GLP-1 receptor (GLP1R) and GLP-2 receptor (GLP2R), were taken during esophagogastroduodenoscopy. The control group consisted of patients with normal endoscopy and negative serology. The CD group consisted of patients with positive serology and endoscopy suggestive of CD. All had an oral glucose-tolerance test (OGTT). CD patients underwent a second OGTT after 6 months of a gluten-free diet (GFD).Results:The CD group included 12 patients; 7 males with mean age 9.2 ± 2.5 years. The control group included 10 patients; 5 males with mean age 12 ± 4 years, (p = 0.14). No differences were detected in basal or peak levels of GLP-1 or GLP-2 between control, naïve CD (before GFD) and treated CD (after GFD) groups. Expression of GLP1R and GLP2R mRNA was similar. Significant positive correlations between glucose and C-peptide secretion (r = 0.9, p < 0.01) and GLP-1 and GLP-2 (r = 0.8, p = 0.01) were detected in the control group. Significant negative correlations were found in the naïve CD group between GLP2R expression and glucose secretion (r = −0.68, p = 0.015) and GLP1R expression and serum GLP-1 (r = −0.7, p = 0.016).Conclusions:Although no significant differences were detected in secretion patterns or gut receptor expression of GLP-1 and GLP-2 in healthy versus CD pediatric patients, the detected discrepancy between the ligand levels and their tissue receptors requires additional study.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-18T05:11:59Z
      DOI: 10.1177/1756284819842756
      Issue No: Vol. 12 (2019)
  • Switching from infliximab to biosimilar in inflammatory bowel disease:
           overview of the literature and perspective

    • Authors: Ágnes Milassin, Anna Fábián, Tamás Molnár
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; however, the approval was based on extrapolated data from rheumatoid arthritis and ankylosing spondylitis. Our aim was to review clinical studies about switching from originator infliximab (IFX-O) to biosimilar infliximab (IXF-B) in IBD, focusing on recently published data and the future of biosimilars.Methods:The PubMed database was searched for original articles published up to 1 December 2018 reporting data on IFX-B in IBD.Results:A total of 29 studies assessing switching from IFX-O to IFX-B, 14 assessing induction therapy with IFX-B were found. Efficacy, safety and immunogenicity were discussed. Studies confirm that CT-P13 is safe and equally efficient as the reference product for both induction and maintenance therapy; and that switching from the reference product to biosimilar is non-inferior to continuous biosimilar use. However, efficacy and safety data on Flixabi (SB2) in IBD patients is lacking.Conclusion:Switching from the originator to a biosimilar in patients with IBD is acceptable, although scientific and clinical evidence is lacking regarding reverse switching, multiple switching and cross-switching among biosimilars in IBD patients.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-16T06:26:43Z
      DOI: 10.1177/1756284819842748
      Issue No: Vol. 12 (2019)
  • Impact of patient and disease characteristics on the efficacy and safety
           of eluxadoline for IBS-D: a subgroup analysis of phase III trials

    • Authors: Brian E. Lacy, Lucinda A. Harris, Lin Chang, Susan Lucak, Catherine Gutman, Leonard S. Dove, Paul S. Covington, Anthony Lembo
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent gastrointestinal (GI) disorder with a varied presentation, often overlapping with other GI and non-GI disorders. Eluxadoline is a locally active mixed µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist approved for the treatment of IBS-D in adults. As IBS-D is a heterogeneous disease, factors such as patient demographics, symptom severity, and symptom pattern history can potentially inform treatment selection.Methods:Here, we report additional prospectively planned analyses of two large double-blind, placebo-controlled studies (IBS-3001 and IBS-3002) enrolling patients meeting Rome III criteria for IBS-D. Patients were randomized 1:1:1 to receive placebo or eluxadoline 75 mg or 100 mg twice daily. Efficacy (abdominal pain, stool consistency, and composite, simultaneous improvement in both) and safety were assessed for prospectively defined patient subgroups stratified by age, sex, race, presence of comorbidities, and baseline disease characteristics.Results:Across all age, sex, race, comorbidity, and disease characteristic subgroups, a greater proportion of patients were composite responders with both eluxadoline doses as compared with placebo, including patients with a history of depression or a history of gastroesophageal reflux disease. Among patients aged ⩾65 years, a greater proportion of patients receiving eluxadoline 75 mg were composite, abdominal pain, and stool consistency responders compared with those receiving 100 mg. The proportion of patients with at least one adverse event was slightly higher in patients aged ⩾65 years and also in female patients.Conclusions:This analysis suggests that eluxadoline is effective in treating IBS-D across a range of commonly encountered patient types. In contrast to the overall population, patients aged ⩾65 years demonstrated a greater proportion of responders at the lower approved 75 mg eluxadoline dose.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-15T10:54:06Z
      DOI: 10.1177/1756284819841290
      Issue No: Vol. 12 (2019)
  • Cell-free DNA testing: future applications in gastroenterology and

    • Authors: Inuk Zandvakili, Konstantinos N. Lazaridis
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      The application of next-generation sequencing in clinical practice is increasing as accuracy and interpretation have improved and the cost continues to decline rapidly. Cell-free DNA is a unique source for next-generation sequencing that could change routine clinical practice in gastroenterology and hepatology. Testing of cell-free DNA in blood and fecal samples is an easy, rapid, and noninvasive method to assess for premalignant, malignant, metabolic, infectious, inflammatory, and autoimmune gastrointestinal and liver diseases. In this review, we describe cell-free DNA technologies, current applications of cell-free DNA testing, and proposed cell-free DNA targets for gastrointestinal and hepatic diseases, with a specific focus on malignancy. In addition, we provide commentary on how cell-free DNA can be integrated into clinical practice and help guide diagnosis, prognosis, disease management, and therapeutic response.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-15T10:19:24Z
      DOI: 10.1177/1756284819841896
      Issue No: Vol. 12 (2019)
  • Cost savings following faecal microbiota transplantation for recurrent
           Clostridium difficile infection

    • Authors: Emilie Dehlholm-Lambertsen, Bianca K. Hall, Simon M. D. Jørgensen, Christine W. Jørgensen, Mia E. Jensen, Sara Larsen, Josephine S. Jensen, Lars Ehlers, Jens F. Dahlerup, Christian L. Hvas
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Recurrent Clostridium difficile infection (rCDI) is becoming increasingly common. Faecal microbiota transplantation (FMT) is effective for rCDI, but the costs of an FMT and hospital cost savings related to FMT are unknown. The aim of this study was to calculate the cost of an FMT and the total hospital costs before and after FMT.Methods:This was an observational single-centre study, carried out in a public teaching hospital. We included all patients referred for rCDI from January 2014 through December 2015 and documented costs related to donor screening, laboratory processing, and clinical FMT application. We calculated patient-related hospital costs 1 year before FMT (pre-FMT) and 1 year after FMT (post-FMT). Sensitivity analyses were applied to assess the robustness of the results.Results:We included 50 consecutive adult patients who had a verified diagnosis of rCDI and were referred for FMT. The average cost of an outpatient FMT procedure if donor faeces were applied by colonoscopy was €3,326 per patient and €2,864 if donor faeces were applied using a nasojejunal tube. The total annual pre-FMT hospital costs per patient were €56,415 (95% confidence interval (CI) 41,133–71,697), and these costs dropped by 42% to €32,816 (22,618–42,014) post-FMT (p = 0.004). The main cost driver was hospital admissions. Sensitivity analyses demonstrated cost reductions in all scenarios.Conclusions:In a public hospital with an implemented FMT service, the average cost of FMT applied by either colonoscopy or nasojejunal tube was €3,095. Total hospital costs dropped by 42% the first year after FMT. The reduction was mainly caused by reductions in the number of hospital admissions and in length of stay.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-11T05:17:58Z
      DOI: 10.1177/1756284819843002
      Issue No: Vol. 12 (2019)
  • Gastrointestinal and liver diseases and atrial fibrillation: a review of
           the literature

    • Authors: Michelle T. Long, Darae Ko, Lindsay M. Arnold, Ludovic Trinquart, Jason A. Sherer, Sunny-Skye Keppel, Emelia J. Benjamin, Robert H. Helm
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Atrial fibrillation (AF) is the most common arrhythmia worldwide and is associated with significant morbidity and mortality. A number of risk factors have been associated with AF, though few studies have explored the association between gastrointestinal and liver diseases and AF. Additionally, AF and treatment for AF may predispose to gastrointestinal and liver diseases. We review the current literature on the bidirectional associations between gastrointestinal and liver diseases and AF. We highlight the gaps in knowledge and areas requiring future investigation.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-04-03T05:24:20Z
      DOI: 10.1177/1756284819832237
      Issue No: Vol. 12 (2019)
  • The gut virome: the ‘missing link’ between gut bacteria and
           host immunity'

    • Authors: Indrani Mukhopadhya, Jonathan P. Segal, Simon R. Carding, Ailsa L. Hart, Georgina L. Hold
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      The human gut virome includes a diverse collection of viruses that infect our own cells as well as other commensal organisms, directly impacting on our well-being. Despite its predominance, the virome remains one of the least understood components of the gut microbiota, with appropriate analysis toolkits still in development. Based on its interconnectivity with all living cells, it is clear that the virome cannot be studied in isolation. Here we review the current understanding of the human gut virome, specifically in relation to other constituents of the microbiome, its evolution and life-long association with its host, and our current understanding in the context of inflammatory bowel disease and associated therapies. We propose that the gut virome and the gut bacterial microbiome share similar trajectories and interact in both health and disease and that future microbiota studies should in parallel characterize the gut virome to uncover its role in health and disease.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-26T04:51:23Z
      DOI: 10.1177/1756284819836620
      Issue No: Vol. 12 (2019)
  • Proton-pump inhibitors do not influence clinical outcomes in patients with
           Staphylococcus aureus bacteremia

    • Authors: Aisling R. Caffrey, Tristan T. Timbrook, Syed Raza Ali, Victor Nizet, George Sakoulas
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Proton-pump inhibitors (PPIs) are commonly used in clinical practice for gastric acid suppression. However, these agents have also been associated with certain negative clinical outcomes. We evaluated the real-world effects of incident PPI use on clinical outcomes in patients with Staphylococcus aureus bacteremia.Methods:This retrospective cohort study included patients admitted to Veterans Affairs hospitals with positive S. aureus blood cultures collected between 2002 and 2013 that received appropriate antibiotics within 48 hours of culture collection. Clinical outcomes among three PPI exposure groups, each compared to nonusers, were assessed with propensity-score-matched Cox proportional-hazard regression models: pretreated PPI users initiating therapy in the 30 days prior to culture and either (a) continuing PPI therapy after culture, or (b) not continuing after culture, and (c) de novo users initiating at culture.Results:Clinical outcomes, including inpatient mortality, intensive care discharge, 30-day mortality, 30-day readmission, and 30-day Clostridium difficile infection (CDI) were similar among PPI users and nonusers. Though length of stay was longer in pretreated, continuing PPI users [time-to-discharge hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.65–0.93], 14-day mortality was significantly lower than in nonusers (HR 0.66, 95% CI 0.50–0.87).Conclusions:In our large national cohort study, PPIs were not associated with an increased risk of negative clinical outcomes, including mortality and CDI, in patients with S. aureus bacteremia.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-22T04:45:00Z
      DOI: 10.1177/1756284819834273
      Issue No: Vol. 12 (2019)
  • 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC:
           implications for therapeutic strategy in curative and non-curative

    • Authors: Arno Kornberg, Helmut Friess
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Hepatocellular carcinoma (HCC) is a global health issue with increasing incidence and high mortality rate. Depending on the tumor load and extent of underlying liver cirrhosis, aggressive surgical treatment by hepatectomy or liver transplantation (LT) may lead to cure, whereas different modalities of liver-directed locoregional or systemic tumor treatments are currently available for a noncurative approach. Apart from tumor burden and grade of liver dysfunction, assessment of prognostic relevant biological tumor aggressiveness is vitally important for establishing a promising multimodal therapeutic strategy and improving the individual treatment-related risk/benefit ratio. In recent years, an increasing body of clinical evidence has been presented that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET), which is a standard nuclear imaging device in oncology, may serve as a powerful surrogate for tumor invasiveness and prognosis in HCC patients and, thereby, impact individual decision making on most appropriate therapy concept. This review describes the currently available data on the prognostic value of 18F-FDG PET in patients with early and advanced HCC stages and the resulting implications for treatment strategy.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-20T05:17:02Z
      DOI: 10.1177/1756284819836205
      Issue No: Vol. 12 (2019)
  • Anorectal biofeedback: an effective therapy, but can we shorten the course
           to improve access to treatment'

    • Authors: Yoav Mazor, John E. Kellow, Gillian M. Prott, Michael P. Jones, Allison Malcolm
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Instrumented anorectal biofeedback (BF) improves symptoms and quality of life in patients with faecal incontinence and defecation disorder-associated chronic constipation. However, demand for BF greatly outweighs availability, so refinement of the BF protocol, in terms of the time and resources required, is of importance. Our aim was to evaluate the outcomes of an abbreviated BF protocol in patients with defecation disorder-associated chronic constipation and/or faecal incontinence compared to standard BF.Methods:Data were collected from consecutive patients (n = 31; age 54 ± 15; 29 females; 61% functional constipation) undergoing an intentionally abbreviated BF protocol, and compared in a 1:2 ratio with 62 age, gender and functional anorectal disorder-matched control patients undergoing a standard BF. Outcomes included change in symptoms, physiology, patient satisfaction and quality of life.Results:On intention to treat, patients in both protocols showed significant improvement in symptom scores and the magnitude did not differ between groups. Impact on quality of life, satisfaction and control over bowel movements improved in both protocols, but satisfaction improved to a greater extent in the standard BF protocol (p = 0.009). Physiological parameters were unchanged after BF apart from improvement in rectal sensation in the standard BF group compared to abbreviated BF (p ⩽ 0.002).Conclusions:Abbreviated anorectal BF offered to patients travelling from far away was not different to a standard BF in providing substantial, at least short term, improvements in symptoms of constipation and faecal incontinence, quality of life and feeling of control over bowel movements. Refinement of the standard BF protocol according to individual patient phenotypes and desired outcomes warrants further study in order to maximize efficacy and improve access for patients.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-20T05:16:34Z
      DOI: 10.1177/1756284819836072
      Issue No: Vol. 12 (2019)
  • Insights into the role of fecal microbiota transplantation for the
           treatment of inflammatory bowel disease

    • Authors: Alexander N. Levy, Jessica R. Allegretti
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Fecal microbiota transplantation (FMT) has changed the treatment landscape of Clostridium difficile infection (CDI). Emerging evidence has shown that FMT can also be an effective and safe treatment strategy in CDI with underlying inflammatory bowel disease (IBD). Recently, randomized controlled trials of FMT in ulcerative colitis support its expanding role in restoring gut homeostasis in this disease. However, heterogeneous study designs leave several questions yet to be answered, including how to best position this novel therapy in the treatment approach of Crohn’s disease and pouchitis. Additional studies are needed to validate whether FMT can assume a complementary role in the standard treatment of IBD.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-15T06:47:25Z
      DOI: 10.1177/1756284819836893
      Issue No: Vol. 12 (2019)
  • Long-term use of proton-pump inhibitors and risk of gastric cancer: a
           review of the current evidence

    • Authors: Ka Shing Cheung, Wai K. Leung
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Gastric cancer remains one of the leading cancers in the world with a high mortality, particularly in East Asia. Helicobacter pylori infection accounts for the majority of the noncardia gastric cancers by triggering gastric inflammation and subsequent neoplastic progression. Eradication of H. pylori can reduce, but not totally eliminate, subsequent risk of developing gastric cancer. Proton-pump inhibitors (PPIs) are one of the most widely prescribed medications worldwide. With their profound gastric-acid suppression, there are concerns about a possible carcinogenic role in gastric cancer, due to induced hypergastrinemia, gastric atrophy and bacterial overgrowth in the stomach. While randomized clinical trials to establish causality between long-term PPI use and gastric cancer are lacking, current evidence based on observational studies suggests PPIs are associated with an increased gastric cancer risk. However, opinions on causality remain divergent due to unmeasured and possible residual confounding in various studies. Our recent study has showed that even after H. pylori eradication, long-term PPI use is still associated with an increased risk of gastric cancer by more than twofold. Hence, long-term PPIs should be used judiciously after considering individual’s risk–benefit profile, particularly among those with history of H. pylori infection. Further well-designed prospective studies are warranted to confirm the potential role of PPIs in gastric cancer according to baseline gastric histology and its interaction with other chemopreventive agents like aspirin, statins and metformin.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-03-12T06:01:22Z
      DOI: 10.1177/1756284819834511
      Issue No: Vol. 12 (2019)
  • Accuracy of the new rapid test for monitoring adalimumab levels

    • Authors: Cátia Rocha, Joana Afonso, Paula Lago, Bruno Arroja, Ana I. Vieira, Claudia C. Dias, Fernando Magro
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the target dosage adjustment to the subsequent infusion. In this study, we aimed to evaluate the performance of the newly available rapid-test ADL quantification assay by comparing it with three established ELISA methods, using spiked samples and a set of clinical samples.Methods:Spiked samples from control donors and 120 serum samples from inflammatory bowel disease (IBD) patients undergoing ADL therapy were quantified using lateral flow Quantum Blue® Adalimumab and, the ELISA formats from Immundiagnostik, R-Biopharm and an in-house assay.Results:The rapid-test assay had intraclass correlation coefficients of 0.590, 0.864 and 0.761 when comparing with the Immundiagnostik, R-Biopharm and in-house assays, respectively. For the five therapeutic windows, the accuracy was high: ADL rapid test compared with the Immundiagnostik (58–88%); R-Biopharm, 68–89%; and in house, 60–88%; and kappa statistics revealed 0.492–0.602, 0.531–0.659 and 0.545–0.682, respectively.Conclusions:The Quantum Blue® Adalimumab assay can replace the commonly used ELISA-based ADL quantification kits and it is a reliable alternative to these methods. This rapid-test assay enables the quantitative determination of ADL serum trough level in only 15 min. The developed assay allows measurement of ADL over a wide range. Hence, it represents a valuable tool for the clinician to assess the ADL trough level.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-02-28T04:30:04Z
      DOI: 10.1177/1756284819828238
      Issue No: Vol. 12 (2019)
  • Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion
           by epithelial–mesenchymal transition in gastric cancer

    • Authors: Kecheng Zhang, Canrong Lu, Xiaohui Huang, Jianxin Cui, Jiyang Li, Yunhe Gao, Wenquan Liang, Yi Liu, Yang Sun, Hanxuan Liu, Bo Wei, Lin Chen
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:The clinical relevance and biological role of tissular AOC4P in gastric cancer (GC) remains to be clarified.Methods:The association between AOC4P expression and clinicopathological characteristics was investigated. In vitro, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, wound healing and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were performed to explore the biological effects of AOC4P on GC cell proliferation, migration, invasion, and apoptosis in MGC-803 and BGC-823 cell lines. In vivo, animal experiments were conducted to confirm the in vitro findings. Quantitative real-time polymerase chain reaction, western blotting, and immunofluorescence were used to investigate the potential mechanisms.Results:Expression levels of AOC4P were significantly higher in tumor tissues than in noncancerous tissues, and patients with high levels of AOC4P had poor overall and disease-free survival. AOC4P expression was correlated with lymphovascular invasion. In vitro, knockdown of AOC4P inhibited tumor cell proliferation, migration, and invasion, and promoted apoptosis of MGC-803 and BGC-823 cells. In vivo, BGC-823 cells transfected with AOC4P siRNA formed smaller and lighter tumors than BGC-823 cells transfected with negative control siRNA in severe combined immunodeficiency mice. Additionally, the si-AOC4P group had less proliferating cells and more apoptotic cells in tumor xenografts compared with the negative control. Mechanistically, knockdown of AOC4P decreased the expression of vimentin and MMP9, while increasing the expression of E-cadherin. Immunofluorescence confirmed the relationship between AOC4P expression and E-cadherin, vimentin, and MMP9 levels in clinical GC specimens.Conclusions:AOC4P promotes tumorigenesis and progression partly through epithelial–mesenchymal transition in GC. Additionally, AOC4P may serve as a prognostic biomarker for clinical decision making.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-02-20T05:17:20Z
      DOI: 10.1177/1756284819827697
      Issue No: Vol. 12 (2019)
  • Symptoms compatible with functional bowel disorders are common in patients
           with quiescent ulcerative colitis and influence the quality of life but
           not the course of the disease

    • Authors: Georgios Mavroudis, Magnus Simren, Börje Jonefjäll, Lena Öhman, Hans Strid
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Whether patients with inactive ulcerative colitis (UC) have symptoms compatible with functional bowel disorders (FBDs) other than irritable bowel syndrome (IBS) is unclear. Our aim was to investigate the prevalence and burden of these symptoms and determine impact on the UC course.Methods:We used Mayo score, sigmoidoscopy and calprotectin (f-cal) to define remission in 293 UC patients. Presence of symptoms compatible with FBD, severity of gastrointestinal, extraintestinal and psychological symptoms, stress levels and quality of life (QoL) were measured with validated questionnaires. At 1 year later, remission was determined by modified Mayo score and f-cal in 171 of these patients. They completed the same questionnaires again.Results:A total of 18% of remission patients had symptoms compatible with FBD other than IBS, and 45% subthreshold symptoms compatible with FBD. The total burden of gastrointestinal symptoms in patients with symptoms compatible with FBD was higher than in patients without FBD (p < 0.001), which had negative impact on QoL (p = 0.02). These symptoms were not correlated with psychological distress, systemic immune activity or subclinical colonic inflammation and were not a risk factor for UC relapse during follow up.Conclusion:Symptoms compatible with FBD other than IBS are common during UC remission influencing patients’ QoL but not the UC course.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-02-20T05:16:45Z
      DOI: 10.1177/1756284819827689
      Issue No: Vol. 12 (2019)
  • Incidence of inflammatory bowel disease by race and ethnicity in a
           population-based inception cohort from 1970 through 2010

    • Authors: Satimai Aniwan, W. Scott Harmsen, William J. Tremaine, Edward V. Loftus
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Background:Although inflammatory bowel disease (IBD) has been more predominant in white populations, an increasing incidence of IBD in nonwhites has been reported. We sought to evaluate the incidence rates and temporal trends of IBD by race and ethnicity.Methods:The resources of the Rochester Epidemiologic Project were used to identify 814 county residents newly diagnosed with IBD from 1970 through 2010. Race was categorized into whites and nonwhites. Ethnicity was categorized into Hispanic and non-Hispanic. Incidence rates were estimated and adjusted for age and sex to the 2010 United States (US) population. Trends in incidence rates were evaluated by Poisson regression.Results:The adjusted annual incidence rate of IBD for whites was 21.6 cases per 100,000 person-years [95% confidence interval (CI), 20.0–23.1] and for nonwhites it was 13 per 100,000 (95% CI, 8.3–17.5). The incidence rates for whites and nonwhites increased by 39% and 134%, respectively, from 1970 through 2010. The adjusted annual incidence rate of IBD for Hispanics was 15 cases per 100,000 person-years (95% CI, 6.3–23.6) and for non-Hispanics was 20 per 100,000 (95% CI, 18.5–21.6). The incidence rate for Hispanics decreased by 56%, while the rate for non-Hispanics increased by 33%, from 1985 through 2010. In a Poisson regression, white race (p < 0.0001), a later year of diagnosis (p < 0.001), male sex (p < 0.001) and younger age (p = 0.009) were significantly associated with a higher incidence rate of IBD.Conclusions:There were significant racial and ethnic differences in the incidence and temporal trends of IBD over the last four decades in this US population-based cohort.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-02-07T06:58:04Z
      DOI: 10.1177/1756284819827692
      Issue No: Vol. 12 (2019)
  • Golimumab in the treatment of ulcerative colitis

    • Authors: Georgina Cunningham, Mark A. Samaan, Peter M. Irving
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.
      Golimumab was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate-to-severe ulcerative colitis in 2013 and was the third antitumour-necrosis-factor therapy after adalimumab and infliximab licensed for this indication. However, given it is the most recent of these drugs to become available, evidence regarding its optimal use and its positioning in relation to other biological therapies is only now emerging. In this article, we review the efficacy, effectiveness and safety of golimumab both in the setting of clinical trials and in ‘real world’ observational studies. We also explore the limited data available regarding the possible role of therapeutic-drug monitoring and dose flexibility.
      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-29T06:01:28Z
      DOI: 10.1177/1756284818821266
      Issue No: Vol. 12 (2019)
  • The application of omics techniques to understand the role of the gut
           microbiota in inflammatory bowel disease

    • Authors: Jonathan P. Segal, Benjamin H. Mullish, Mohammed Nabil Quraishi, Animesh Acharjee, Horace R. T. Williams, Tariq Iqbal, Ailsa L. Hart, Julian R. Marchesi
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-25T05:55:55Z
      DOI: 10.1177/1756284818822250
      Issue No: Vol. 12 (2019)
  • Personalized management in functional gastrointestinal disorders based on
           genomics: hope at last or just feigned praise'

    • Authors: Xiao Jing (Iris) Wang, Michael Camilleri
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-24T06:30:04Z
      DOI: 10.1177/1756283X18822791
      Issue No: Vol. 12 (2019)
  • Targeting liver cancer stem cells for the treatment of hepatocellular

    • Authors: Na Li, Ying Zhu
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-23T05:36:50Z
      DOI: 10.1177/1756284818821560
      Issue No: Vol. 12 (2019)
  • Acupuncture and related therapies for treating irritable bowel syndrome:
           overview of systematic reviews and network meta-analysis

    • Authors: Irene X. Y. Wu, Charlene H. L. Wong, Robin S. T. Ho, William K. W. Cheung, Alexander C. Ford, Justin C. Y. Wu, Arthur D. P. Mak, Holger Cramer, Vincent C. H. Chung
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-21T06:15:28Z
      DOI: 10.1177/1756284818820438
      Issue No: Vol. 12 (2019)
  • The intestinal vitamin D receptor in inflammatory bowel disease: inverse
           correlation with inflammation but no relationship with circulating vitamin
           D status

    • Authors: Mayur Garg, Simon G. Royce, Chris Tikellis, Claire Shallue, Pavel Sluka, Hady Wardan, Patrick Hosking, Shaun Monagle, Merlin Thomas, John S. Lubel, Peter R. Gibson
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-18T10:41:03Z
      DOI: 10.1177/1756284818822566
      Issue No: Vol. 12 (2019)
  • Practical guidance for the management of inflammatory bowel disease in
           patients with cancer. Which treatment'

    • Authors: Shaji Sebastian, Steven Neilaj
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-04T11:28:41Z
      DOI: 10.1177/1756284818817293
      Issue No: Vol. 12 (2019)
  • Factors associated with more frequent diagnostic tests and procedures in
           patients with irritable bowel syndrome

    • Authors: Brian Lacy, Rajeev Ayyagari, Annie Guerin, Andrea Lopez, Sherry Shi, Michelle Luo
      Abstract: Therapeutic Advances in Gastroenterology, Volume 12, Issue , January-December 2019.

      Citation: Therapeutic Advances in Gastroenterology
      PubDate: 2019-01-02T07:12:41Z
      DOI: 10.1177/1756284818818326
      Issue No: Vol. 12 (2019)
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-